Vitamin D Supplementation on Physical and Cognitive Function-Pilot Study
This study is currently recruiting participants.
Verified February 2017 by VA Office of Research and Development
Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT01229878
First received: October 26, 2010
Last updated: February 17, 2017
Last verified: February 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a double-blind placebo controlled pilot study to determine if vitamin D supplementation in hemodialysis (HD) patients will improve physical function and cognition. HD patients have a high prevalence of vitamin D deficiency, cognitive impairment, and physical impairment. Despite standard clinical care with active IV vitamin D during dialysis, HD patients still have markedly low levels of nutritional or dietary vitamin D. IV treatment with vitamin D during dialysis is aimed at treating HD related bone disease. Recent literature shows that oral or nutritional vitamin D has multiple extra-skeletal effects including improvement in cognition and physical function. In this study, the investigators plan to administer oral vitamin D to vitamin D deficient HD patients already receiving standard care with IV vitamin D therapy. Patients will be randomized to receive either placebo or 50,000 IU of vitamin D (cholecalciferol) weekly for 6 months. The investigators' specific aims are to 1) Assess the benefits of correcting nutritional vitamin D deficiency on cognitive and physical function in HD patients receiving routine standard of care, 2) Assess the feasibility of recruiting HD patients for this study, and 3) Evaluate the proposed regimen for safely and effectively increasing nutritional vitamin D levels with oral supplementation. The investigators anticipate that correction of nutritional vitamin D deficiency to optimal levels will improve the high prevalence of cognitive impairment and physical impairment in this population. These results will be used as evidence to support a larger study aimed at treating nutritional vitamin D deficiency in all patients receiving HD. These results may also contribute to a change in current guidelines which place little emphasis on the monitoring and treatment of nutritional vitamin D levels in HD patients. These results are important for the Veteran dialysis population since many of them are required to perform high-level cognitive tasks such as management of complex medical regimens and physical tasks such as orchestrating independent transportation to and from HD sessions and multiple physician appointments.
| Condition | Intervention |
|---|---|
| Renal Dialysis Vitamin D Deficiency | Dietary Supplement: Cholecalciferol (Vitamin D) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Care Provider, Investigator, Outcomes Assessor Primary Purpose: Treatment |
| Official Title: | Vitamin D Supplementation on Physical and Cognitive Function-Pilot Study |
Resource links provided by NLM:
Further study details as provided by VA Office of Research and Development:
Primary Outcome Measures:
- Neuromuscular Function [ Time Frame: 6 months ]
Secondary Outcome Measures:
- Quality-of-Life self assessment [ Time Frame: 6 months ]
- Neuropsychological assessments [ Time Frame: 6 months ]
- Immune Function assessments [ Time Frame: 6 months ]
| Estimated Enrollment: | 50 |
| Actual Study Start Date: | December 1, 2011 |
| Estimated Study Completion Date: | June 2018 |
| Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Arm 1
Hemodialysis Patients randomized to take Vitamin D supplements
|
Dietary Supplement: Cholecalciferol (Vitamin D)
50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
|
|
Placebo Comparator: Arm 2
Hemodialysis Patients randomized to take placebo pills
|
Dietary Supplement: Cholecalciferol (Vitamin D)
50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
|
Detailed Description:
Background:
Objectives:
Methods:
Status:
Eligibility| Ages Eligible for Study: | 45 Years to 89 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Receiving HD for at least two weeks
- Receiving IV vitamin D supplementation according to National Kidney Foundation guidelines.
- Male or female with an between the ages of 45-89 years
- Veteran outpatient or stable community living center patient
- Able to ambulate independently or with an assistive device for at least 20 feet
Exclusion Criteria:
- 25-OH vitamin D level < 25 ng/ml
- Hypercalcemia
- Active malignancy within 6 months
- Receiving intravenous antibiotics for infection
- History of Dementia
- Hemoglobin < 8.5g
- History of conditions that interfere with postural instability (e.g. cerebellar disease, vestibular disease or any others that may present)
- Poor compliance with dialysis treatments (history of skipping 2 treatments per month for > 2 months)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01229878
Please refer to this study by its ClinicalTrials.gov identifier: NCT01229878
Contacts
| Contact: Kel G Morin | (718) 584-9000 ext 5129 | Kel.Morin@va.gov | |
| Contact: James B Post, MD | (718) 584-9000 ext 6635 | james.post@va.gov |
Locations
| United States, New York | |
| James J. Peters VA Medical Center, Bronx, NY | Recruiting |
| Bronx, New York, United States, 10468 | |
| Contact: Kel G Morin 718-584-9000 ext 5129 Kel.Morin@va.gov | |
| Principal Investigator: James B Post, MD | |
Sponsors and Collaborators
VA Office of Research and Development
Investigators
| Principal Investigator: | James B Post, MD | VA Office of Research and Development |
More Information
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT01229878 History of Changes |
| Other Study ID Numbers: |
F7539-P |
| Study First Received: | October 26, 2010 |
| Last Updated: | February 17, 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
Additional relevant MeSH terms:
|
Vitamin D Deficiency Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Vitamins Vitamin D |
Ergocalciferols Cholecalciferol Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on July 14, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
